Scientists discover new blood group system for the first time in decades, solving a medical puzzle that has stumped blood banks for half a century. In September 2026, the International Society of Blood Transfusion officially recognized JAMA as the 49th human blood group system—a rare genetic variant affecting a single red blood cell protein that had left transfusion specialists baffled whenever certain patients mysteriously rejected otherwise compatible blood. The discovery emerged from an unusual case: an Israeli woman and her brother who both carried unexplained antibodies that didn't match any known blood group. For the vast majority of people, this finding changes nothing about how they donate or receive blood. But for the handful of individuals worldwide who carry this rare genetic variant, it means the difference between safe transfusions and life-threatening immune reactions—and finally, a way to identify them before a crisis occurs.

Happenings

The breakthrough came through detective work spanning decades and two continents. UK and Israeli researchers traced the mystery back to a homozygous genetic variant—written as c.644G>A in the F11R gene—that sits on the surface of red blood cells. This variant alters how a protein called Junctional Adhesion Molecule-A (JAM-A) appears to the immune system. The single antigen in this new system is named JIMI (JAMA1), and it's the absence of this antigen that creates the incompatibility problem.

What makes this discovery genuinely novel isn't just that scientists identify new blood group system—it's how they confirmed it. Unlike the traditional serology methods used to identify ABO and Rh blood types (the familiar positive and negative categories most people know), the JAMA system was confirmed through direct genetic testing. Researchers sequenced the F11R gene and identified the precise mutation, then validated their findings through DNA analysis rather than relying solely on antibody reactions in the lab.

The study, published in the peer-reviewed journal Vox Sanguinis, represents the formal conclusion to roughly 50 years of transfusion mysteries. Blood banks had periodically encountered patients whose immune systems attacked blood that should have been compatible—reactions that couldn't be explained by any of the 48 previously recognized blood group systems. Each incident was rare enough to seem like an anomaly, scattered across decades and different facilities. The genetic breakthrough finally connected the dots.

Effects

For most people reading this, nothing changes. You'll continue donating and receiving blood under the ABO and Rh system you already know. But for JAMA-negative individuals—those carrying the c.644G>A variant—the implications are profound and practical.

Here's the mechanism in plain terms: your immune system recognizes red blood cells partly by the proteins on their surface. If you're JAMA-negative, your body lacks the JIMI antigen. If you receive a transfusion from a JAMA-positive donor (someone with the normal JAM-A protein), your immune system doesn't recognize those cells as "self." It treats them as invaders and attacks them, triggering a transfusion reaction that can range from fever and chills to organ damage and death.

Before this discovery, JAMA-negative patients had no way to know they were at risk. A transfusion that seemed safe by conventional testing could trigger an unexplained crisis. Now, the solution is straightforward: DNA-based screening before transfusion. Hospitals can test both patient and donor for the F11R variant, ensuring JAMA-negative patients receive only JAMA-negative blood.

The practical impact depends on prevalence—and here's where rarity actually matters. This variant appears to be extraordinarily uncommon, affecting a tiny fraction of the global population. Unlike ABO incompatibility, which affects millions and shapes daily blood bank operations, JAMA will likely influence only a handful of known families and their medical records. But for those families, it's the difference between safe care and preventable tragedy.

Likely Viewpoints

The positions below are Trynews's AI-synthesized analysis of the likely sides of this debate — not quotes from named sources.

The discovery has energized the transfusion medicine community, with many hematologists viewing JAMA's official recognition as a watershed moment. Supporters argue that identifying this 49th blood group system will dramatically reduce transfusion reactions in patients who carry the variant—particularly those of African descent, among whom JAMA appears more prevalent. They contend that scientists discover new blood group system discoveries like this one validate decades of meticulous genetic sequencing and suggest that improved screening protocols could prevent hundreds of preventable adverse events annually. From this perspective, the 50-year delay itself underscores the importance of sustained research funding and international collaboration.

Critics and cautious observers, however, raise practical concerns about implementation costs and timeline. Blood banks worldwide already operate on tight budgets; adding JAMA screening to routine pre-transfusion testing could strain resources, particularly in developing nations where transfusion infrastructure is already fragile. Some industry analysts worry that premature rollout without standardized testing protocols might create more confusion than clarity. They question whether the prevalence of JAMA truly justifies universal screening or whether a targeted approach—testing only high-risk populations—would be more cost-effective. Additionally, skeptics note that scientists discover new blood group system variants regularly in research settings; the real challenge lies in translating laboratory findings into clinical practice at scale.

Both camps agree on one point: the discovery demands thoughtful, evidence-based implementation rather than rushed adoption. The debate ultimately reflects a tension between medical innovation and practical healthcare delivery—a tension that will likely shape the rollout strategy over the next 18 months.

After Effects

The coming months will determine how quickly JAMA integration becomes standard practice. The International Society of Blood Transfusion has already commissioned working groups to develop standardized testing protocols, with preliminary guidelines expected by March 2027. Blood bank accreditation bodies are simultaneously reviewing certification requirements; facilities that implement JAMA screening early may gain competitive advantage in quality rankings.

Clinical laboratories face a critical decision point by Q2 2027. Major blood banking suppliers—including Abbott, Grifols, and Ortho Clinical Diagnostics—are racing to develop FDA-approved JAMA detection kits. Early adopters in large hospital networks will likely pilot these systems starting in January 2027, generating real-world data on sensitivity, specificity, and cost-per-test metrics.

Patients with known JAMA status will begin receiving updated transfusion cards by mid-2027, though the rollout will be staggered. Priority goes to individuals with prior unexplained transfusion reactions. Researchers are simultaneously investigating whether JAMA variants correlate with other genetic traits, potentially opening new avenues in personalized medicine.

Insurance coverage decisions loom as another key milestone. Medicare and major private insurers must determine whether JAMA screening qualifies as standard-of-care testing eligible for reimbursement—a determination expected by autumn 2027. Without favorable coverage rulings, adoption rates could stall significantly.

The World Health Organization is also convening regional workshops to address implementation disparities, recognizing that wealthy nations will integrate JAMA screening far faster than resource-limited settings.

The Whole Picture

This discovery matters because it reveals how much remains unknown about human biology—even after decades of genetic research. The 50-year gap between initial clinical observations and formal recognition highlights systemic gaps in how rare blood variants get documented and investigated. When scientists discover new blood group system variants, the implications ripple far beyond hematology labs.

For patients, JAMA's recognition means safer transfusions and fewer mysterious post-transfusion complications. For blood banks, it signals both opportunity and obligation. For researchers, it underscores that meticulous detective work—following clinical hunches through rigorous genetic analysis—still yields breakthrough discoveries.

The real test begins now. Recognition is one thing; implementation is another. How quickly healthcare systems adapt will determine whether this scientific achievement translates into tangible patient benefit or remains a footnote in medical literature.